ReThink Medical, a leading data-driven heart failure medical device and digital health company, announced a Series A investment of $3 million led by medical device equity firm Emergent Medical Partners (EMP).  EMP will lead the round with additional funds coming from investors Norwich Ventures and Launch Capital. 

This is in addition to the two National Institutes of Health (NIH) grants that were awarded to ReThink Medical and a strategic partnership with the Japanese medical device company, Terumo Corporation.  The financing will be used to fund ReThink Medical's clinical trials and for further investment in its proprietary technology platform. Bob Brownell, managing director at EMP, will join ReThink Medical's board of directors.

ReThink Medical uses predictive physiologic data to prevent hospitalizations for heart failure patients.  By monitoring and analyzing data from patients in an ambulatory setting, ReThink's proprietary algorithms can predict worsening conditions and alert physicians to take data-driven proactive measures for their patients.  This prescriptive action can change the trajectory of heart failure patients and thereby eliminate a potential hospitalization.